Development of Duration-Based Non-Mutagenic Thresholds of Toxicological Concern (TTCs) Relevant to Parenteral Extractables and Leachables (E&Ls)

References

1. 1.↵
   1. Ball D.,
   2. Blanchard J.,
   3. Jacobson-Kram D.,
   4. McClellan R. O.,
   5. McGovern T.,
   6. Norwood D. L.,
   7. Vogel W.,
   8. Wolff R.,
   9. Nagao L.

   Development of Safety Qualification Thresholds and Their Use in Orally Inhaled and Nasal Drug Product Evaluation. Toxicol. Sci. 2007, 97 (2), 226–236.

   OpenUrlCrossRefPubMed
2. 2.↵
   1. Jenke D.,
   2. Castner J.,
   3. Egert T.,
   4. Feinberg T.,
   5. Hendricker A.,
   6. Houston C.,
   7. Hunt D. G.,
   8. Lynch M.,
   9. Shaw A.,
   10. Nicholas K.,
   11. Norwood D. L.,
   12. Paskiet D.,
   13. Ruberto M.,
   14. Smith E. J.,
   15. Holcomb F.

   Extractables Characterization for Five Materials of Construction Representative of Packaging Systems Used for Parenteral and Ophthalmic Drug Products. PDA J. Pharm. Sci. Technol. 2013, 67 (5), 448–511.

   OpenUrlAbstract/FREE Full Text
3. 3.↵
   1. Jenke D. R.

   Linking Extractables and Leachables in Container/Closure Applications. PDA J. Pharm. Sci. Technol. 2005, 59 (4), 265–281.

   OpenUrlAbstract/FREE Full Text
4. 4.↵
   1. Jenke D. R.

   Extractables and Leachables Considerations for Prefilled Syringes. Expert Opin. Drug Delivery 2014, 11 (10), 1591–1600.

   OpenUrl
5. 5.↵
   1. Jenke D. R,
   2. Story J.,
   3. Lalani R.

   Extractables/Leachables from Plastic Tubing Used in Product Manufacturing. Int. J. Pharm. 2006, 315 (1-2), 75–92.

   OpenUrlCrossRefPubMedWeb of Science
6. 6.↵
   1. Li K.,
   2. Rogers G.,
   3. Nashed-Samuel Y.,
   4. Lee H.,
   5. Mire-Sluis A.,
   6. Cherney B.,
   7. Forster R.,
   8. Yeh P.,
   9. Markovic I.

   Creating a Holistic Extractables and Leachables (E&L) Program for Biotechnology Products. PDA J. Pharm. Sci. Technol. 2015, 69 (5), 590–619.

   OpenUrlAbstract/FREE Full Text
7. 7.↵
   1. Paskiet D.,
   2. Jenke D.,
   3. Ball D.,
   4. Houston C.,
   5. Norwood D. L.,
   6. Markovic I.

   The Product Quality Research Institute (PQRI) Leachables and Extractables Working Group Initiatives for Parenteral and Ophthalmic Drug Product (PODP). PDA J. Pharm. Sci. Technol. 2013, 67 (5), 430–447.

   OpenUrlAbstract/FREE Full Text
8. 8.↵
   International Conference for Harmonisation, Final Concept Paper ICH Q3E: Guideline for Extractables and Leachables (E&Ls). ICH: Geneva, 2020.
9. 9.↵
   U.S. Food and Drug Administration, Guidance for Industry: Container Closure Systems for Packaging Human Drugs and Biologics; FDA-1997-D-0145; Center for Biologics Evaluation and Research. U.S. Department of Health and Human Services: Rockville, MD, 1999.
10. 10.↵
    1. Broschard T. H.,
    2. Glowienke S.,
    3. Bruen U. S.,
    4. Nagao L. M.,
    5. Teasdale A.,
    6. Stults C. L. M.,
    7. Li K. L.,
    8. Iciek L. A.,
    9. Erexson G.,
    10. Martin E. A.,
    11. Ball D. J.

    Assessing Safety of Extractables from Materials and Leachables in Pharmaceuticals and biologics—Current Challenges and Approaches. Regul. Toxicol. Pharmacol. 2016, 81, 201–211.

    OpenUrl
11. 11.↵
    1. Parris P.,
    2. Martin E. A.,
    3. Stanard B.,
    4. Glowienke S.,
    5. Dolan D. G.,
    6. Li K.,
    7. Binazon O.,
    8. Giddings A.,
    9. Whelan G.,
    10. Masuda-Herrera M.,
    11. Bercu J.,
    12. Broschard T.,
    13. Bruen U.,
    14. Callis C. M.,
    15. Stults C. L. M.,
    16. Erexson G. L.,
    17. Cruz M. T.,
    18. Nagao L. M.

    Considerations When Deriving Compound-Specific Limits for Extractables and Leachables from Pharmaceutical Products: Four Case Studies. Regul. Toxicol. Pharmacol. 2020, 118, 104802.

    OpenUrl
12. 12.↵
    1. Munro I. C.,
    2. Ford R. A.,
    3. Kennepohl E.,
    4. Sprenger J. G.

    Correlation of Structural Class with No-Observed-Effect Levels: A Proposal for Establishing a Threshold of Concern. Food Chem. Toxicol. 1996, 34 (9), 829–867.

    OpenUrlCrossRefPubMedWeb of Science
13. 13.↵
    1. Kroes R.,
    2. Renwick A. G.,
    3. Cheeseman M.,
    4. Kleiner J.,
    5. Mangelsdorf I.,
    6. Piersma A.,
    7. Schilter B.,
    8. Schlatter J.,
    9. van Schothorst F.,
    10. Vos J. G.,
    11. Würtzen G.

    Structure-Based Thresholds of Toxicological Concern (TTC): Guidance for Application to Substances Present at Low Levels in the Diet. Food Chem Toxicol 2004, 42 (1), 65–83.

    OpenUrlCrossRefPubMedWeb of Science
14. 14.↵
    1. Bury D.,
    2. Head J.,
    3. Keller D.,
    4. Klaric M.,
    5. Rose J.

    The Threshold of Toxicological Concern (TTC) is a Pragmatic Tool for the Safety Assessment: Case Studies of Cosmetic Ingredients with Low Consumer Exposure. Regul. Toxicol. Pharmacol. 2021, 123, 104964.

    OpenUrl
15. 15.↵
    1. Dolan D. G.,
    2. Naumann B. D.,
    3. Sargent E. V.,
    4. Maier A.,
    5. Dourson M.

    Application of the Threshold of Toxicological Concern Concept to Pharmaceutical Manufacturing Operations. Regul. Toxicol. Pharmacol. 2005, 43 (1), 1–9.

    OpenUrlCrossRefPubMedWeb of Science
16. 16.↵
    1. Stanard B.,
    2. Dolan D. G.,
    3. Hanneman W.,
    4. Legare M.,
    5. Bercu J. P.

    Threshold of Toxicological Concern (TTC) for Developmental and Reproductive Toxicity of Anticancer Compounds. Regul. Toxicol. Pharmacol. 2015, 72 (3), 602–609.

    OpenUrl
17. 17.↵
    1. Kawamoto T.,
    2. Fuchs A.,
    3. Fautz R.,
    4. Morita O.

    Threshold of Toxicological Concern (TTC) for Botanical Extracts (Botanical-TTC) Derived from a Meta-Analysis of Repeated-Dose Toxicity Studies. Toxicol. Lett. 2019, 316, 1–9.

    OpenUrl
18. 18.↵
    International Conference for Harmonisation, Harmonised Guideline M7(R1): Assessment and Control of DNA Reactive (Mutagenic) Impurities in Pharmaceuticals to Limit Potential Carcinogenic Risk. ICH: Geneva, 2017.
19. 19.↵
    1. Felter S. P.,
    2. Conolly R. B.,
    3. Bercu J. P.,
    4. Bolger P. M.,
    5. Boobis A. R.,
    6. Bos P. M.,
    7. Carthew P.,
    8. Doerrer N. G.,
    9. Goodman J. I.,
    10. Harrouk W. A.,
    11. Kirkland D. J.,
    12. Lau S. S.,
    13. Llewellyn G. C.,
    14. Preston R. J.,
    15. Schoeny R.,
    16. Schnatter A. R.,
    17. Tritscher A.,
    18. van Velsen F.,
    19. Williams G. M.

    A Proposed Framework for Assessing Risk from Less-than-Lifetime Exposures to Carcinogens. Crit. Rev. Toxicol. 2011, 41 (6), 507–544.

    OpenUrlCrossRefPubMed
20. 20.↵
    1. Amberg A.,
    2. Beilke L.,
    3. Bercu J.,
    4. Bower D.,
    5. Brigo A.,
    6. Cross K. P.,
    7. Custer L.,
    8. Dobo K.,
    9. Dowdy E.,
    10. Ford K. A.,
    11. Glowienke S.,
    12. Van Gompel J.,
    13. Harvey J.,
    14. Hasselgren C.,
    15. Honma M.,
    16. Jolly R.,
    17. Kemper R.,
    18. Kenyon M.,
    19. Kruhlak N.,
    20. Leavitt P.,
    21. Miller S.,
    22. Muster W.,
    23. Nicolette J.,
    24. Plaper A.,
    25. Powley M.,
    26. Quigley D. P.,
    27. Reddy M. V.,
    28. Spirkl H.-P.,
    29. Stavitskaya L.,
    30. Teasdale A.,
    31. Weiner S.,
    32. Welch D. S.,
    33. White A.,
    34. Wichard J.,
    35. Myatt G. J.

    Principles and Procedures for Implementation of ICH M7 Recommended (Q)SAR Analyses. Regul. Toxicol. Pharmacol. 2016, 77, 13–24.

    OpenUrl
21. 21.↵
    1. Barber C.,
    2. Amberg A.,
    3. Custer L.,
    4. Dobo K. L.,
    5. Glowienke S.,
    6. Van Gompel J.,
    7. Gutsell S.,
    8. Harvey J.,
    9. Honma M.,
    10. Kenyon M. O.,
    11. Kruhlak N.,
    12. Muster W.,
    13. Stavitskaya L.,
    14. Teasdale A.,
    15. Vessey J.,
    16. Wichard J.

    Establishing Best Practise in the Application of Expert Review of Mutagenicity under ICH M7. Regul. Toxicol. Pharmacol. 2015, 73 (1), 367–377.

    OpenUrl
22. 22.↵
    1. Paskiet D.

    Overview of Thresholds and Best Practices for Extractables and Leachables (L&E). Presented at 3rd PQRI/FDA Conference on Advancing Product Quality, Washington DC, March 22, 2017.
23. 23.↵
    International Organization for Standardization, IS/TS 21726:2019 Biological Evaluation of Medical Devices—Application of the Threshold of Toxicological Concern (TTC) for Assessing Biocompatibility of Medical Device Constituents. ISO: Geneva, 2019.
24. 24.↵
    International Conference for Harmonisation, Harmonised Guideline Q3C(R8): Impurities: Guideline for Residual Solvents. ICH: Geneva, 2021.
25. 25.↵
    International Conference for Harmonisation, ICH M3(R2): Guidance on Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals. ICH: Geneva, 2009.
26. 26.↵
    1. Sussman R. G.,
    2. Naumann B. D.,
    3. Pfister T.,
    4. Sehner C.,
    5. Seaman C.,
    6. Weideman P. A.

    A Harmonization Effort for Acceptable Daily Exposure Derivation—Considerations for Application of Adjustment Factors. Regul. Toxicol. Pharmacol. 2016, 79 (1), S57–66.

    OpenUrl
27. 27.↵
    1. Nelms M. D,
    2. Pradeep P.,
    3. Patlewicz G.

    Evaluating Potential Refinements to Existing Threshold of Toxicological Concern (TTC) Values for Environmentally-Relevant Compounds. Regul. Toxicol. Pharmacol. 2019, 109, 104505.

    OpenUrl
28. 28.↵
    KNIME, 2021.
29. 29.↵
    1. Landrum G.

    The RDKit 2021.03.1 Documentation. 2021.
30. 30.↵
    1. Djoumbou Feunang Y.,
    2. Eisner R.,
    3. Knox C.,
    4. Chepelev L.,
    5. Hastings J.,
    6. Owen G.,
    7. Fahy E.,
    8. Steinbeck C.,
    9. Subramanian S.,
    10. Bolton E.,
    11. Greiner R.,
    12. Wishart D. S.

    ClassyFire: Automated Chemical Classification with a Comprehensive, Computable Taxonomy. J. Cheminform. 2016, 8 (1), 61.

    OpenUrlCrossRefPubMed
31. 31.↵
    International Conference for Harmonisation, Harmonised Guideline Q3D(R1): Guideline for Elemental Impurities. ICH: Geneva, 2019.
32. 32.↵
    1. Harvey J.,
    2. Fleetwood A.,
    3. Ogilvie R.,
    4. Teasdale A.,
    5. Wilcox P.,
    6. Spanhaak S.

    Management of Organic Impurities in Small Molecule Medicinal Products: Deriving Safe Limits for Use in Early Development. Regul. Toxicol. Pharmacol. 2017, 84, 116–123.

    OpenUrl
33. 33.↵
    1. Tluczkiewicz I.,
    2. Buist H. E.,
    3. Martin M. T.,
    4. Mangelsdorf I.,
    5. Escher S. E.

    Improvement of the Cramer Classification for Oral Exposure Using the Database TTC RepDose—A Strategy Description. Regul. Toxicol. Pharmacol. 2011, 61 (3), 340–350.

    OpenUrlPubMed
34. 34.↵
    1. Partosch F.,
    2. Mielke H.,
    3. Stahlmann R.,
    4. Kleuser B.,
    5. Barlow S.,
    6. Gundert-Remy U.

    Internal Threshold of Toxicological Concern Values: Enabling Route-to-Route Extrapolation. Arch. Toxicol. 2015, 89 (6), 941–948.

    OpenUrl
35. 35.↵
    1. Parris P.

    Framework for Sensitization Assessme-nt of Extractables and Leachables in Pharmaceuticals. Critical Reviews in Toxicology, in press.
36. 36.↵
    United Nations. Globally Harmonized System of Classification and Labelling of Chemicals (GHS), 8th revised ed.; United Nations: New York, 2019.
37. 37.↵
    1. Lampe B. J.,
    2. Fuller E.,
    3. Kuppusamy S. P.

    A Quantitative Comparison of Points of Departure between 28-Day and 90-Day Repeated Dose Studies with a Proposed Extrapolation Factor. Regul. Toxicol. Pharmacol. 2018, 92, 189–200.

    OpenUrl